33 related articles for article (PubMed ID: 36216101)
21. The Current Status of O-Heterocycles: A Synthetic and Medicinal Overview.
Singh PK; Silakari O
ChemMedChem; 2018 Jun; 13(11):1071-1087. PubMed ID: 29603634
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of cathepsin B.
Frlan R; Gobec S
Curr Med Chem; 2006; 13(19):2309-27. PubMed ID: 16918357
[TBL] [Abstract][Full Text] [Related]
23. Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development.
Peerzada MN; Hamel E; Bai R; Supuran CT; Azam A
Pharmacol Ther; 2021 Sep; 225():107860. PubMed ID: 33895188
[TBL] [Abstract][Full Text] [Related]
24. A decennary update on applications of metal nanoparticles (MNPs) in the synthesis of nitrogen- and oxygen-containing heterocyclic scaffolds.
Dhameliya TM; Donga HA; Vaghela PV; Panchal BG; Sureja DK; Bodiwala KB; Chhabria MT
RSC Adv; 2020 Sep; 10(54):32740-32820. PubMed ID: 35516511
[TBL] [Abstract][Full Text] [Related]
25. Recent Advances in the Green Synthesis of Active
Majee S; Shilpa ; Sarav M; Banik BK; Ray D
Pharmaceuticals (Basel); 2023 Jun; 16(6):. PubMed ID: 37375820
[No Abstract] [Full Text] [Related]
26. Current status of
Jassas RS; Naeem N; Sadiq A; Mehmood R; Alenazi NA; Al-Rooqi MM; Mughal EU; Alsantali RI; Ahmed SA
RSC Adv; 2023 May; 13(24):16413-16452. PubMed ID: 37274413
[TBL] [Abstract][Full Text] [Related]
27. A decennary update on diverse heterocycles and their intermediates as privileged scaffolds for cathepsin B inhibition.
Saroha B; Kumar G; Kumari M; Kaur R; Raghav N; Sharma PK; Kumar N; Kumar S
Int J Biol Macromol; 2022 Dec; 222(Pt B):2270-2308. PubMed ID: 36216101
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of Medicinally Privileged Heterocycles through Dielectric Heating.
Bandyopadhyay D; Banik BK
Curr Med Chem; 2017; 24(41):4596-4626. PubMed ID: 28240166
[TBL] [Abstract][Full Text] [Related]
29. Structurally diversified heterocycles and related privileged scaffolds as potential urease inhibitors: a brief overview.
Ibrar A; Khan I; Abbas N
Arch Pharm (Weinheim); 2013 Jun; 346(6):423-46. PubMed ID: 23712847
[TBL] [Abstract][Full Text] [Related]
30. A review on diverse heterocyclic compounds as the privileged scaffolds in non-steroidal aromatase inhibitors.
Rani S; Raheja K; Luxami V; Paul K
Bioorg Chem; 2021 Aug; 113():105017. PubMed ID: 34091288
[TBL] [Abstract][Full Text] [Related]
31. Beyond basic research: the contribution of cathepsin B to cancer development, diagnosis and therapy.
Zamyatnin AA; Gregory LC; Townsend PA; Soond SM
Expert Opin Ther Targets; 2022 Nov; 26(11):963-977. PubMed ID: 36562407
[TBL] [Abstract][Full Text] [Related]
32. A review on diverse heterocyclic compounds as the privileged scaffolds in antimalarial drug discovery.
Kalaria PN; Karad SC; Raval DK
Eur J Med Chem; 2018 Oct; 158():917-936. PubMed ID: 30261467
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
